Seib F Philipp, Jones Arwyn T, Duncan Ruth
Welsh School of Pharmacy, Centre for Polymer Therapeutics, Cardiff University, King Edward VII Avenue, Cardiff CF10 3XF, UK.
J Drug Target. 2006 Jul;14(6):375-90. doi: 10.1080/10611860600833955.
Polymer therapeutics are being designed for lysosomotropic, endosomotropic and transcellular drug delivery. Their appropriate intracellular routing is thus crucial for successful use. For example, polymer-anticancer drug conjugates susceptible to lysosomal enzyme degradation will never deliver their drug payload unless they encounter the appropriate activating enzymes. Many studies use confocal microscopy to monitor intracellular fate, but there is a pressing need for more quantitative methods able to define intracellular compartmentation over time. Only then will it be possible to optimise the next generation of polymer therapeutics for specific applications. The aim of this study was to establish a subcellular fractionation method for B16F10 murine melanoma cells and subsequently to use it to define the intracellular trafficking of N-(2-hydroxyproplylmethacrylamide) (HPMA) copolymer-bound doxorubicin (PK1). Free doxorubicin was used as a reference. The cell cracker method was used to achieve cell breakage and optimised to reproducibly achieve approximately 90% breakage efficiency. This ensured that subsequent subcellular fractionation experiments were representative for the whole cell population. To characterise the subcellular fractions obtained by differential centrifugation, DNA (nuclei), succinate dehydrogenase (mitochondria), N-acetyl-beta-glucosaminidase (lysosomes), alkaline phosphatase (plasma membrane) and lactate dehydrogenase (cytosol) were selected as markers and their assay was carefully validated. The relative specific activity (RSA) of the fractions obtained from B16F10 cells were: nuclei (2.2), mitochondria (4.1), lysosomes (3.7) and cytosol (2.5). When used to study the intracellular distribution at non-toxic concentrations of PK1 and doxorubicin, time-dependent accumulation of PK1 in lysosomes was evident and the expected nuclear localisation of free doxorubicin was seen. Live cell fluorescence microscopy and confocal co-localisation studies gave qualitative corroboration of these results, but by using this method, we were unable to accurately define organelle localisation. In conclusion, the B16F10 subcellular fractionation method developed here provides a useful tool to allow comparison of the intracellular trafficking of other polymer conjugates.
聚合物疗法正被设计用于溶酶体亲和性、内体亲和性和跨细胞药物递送。因此,它们合适的细胞内转运途径对于成功应用至关重要。例如,易受溶酶体酶降解的聚合物 - 抗癌药物偶联物,除非遇到合适的激活酶,否则永远无法递送其药物载荷。许多研究使用共聚焦显微镜来监测细胞内命运,但迫切需要更定量的方法来确定随时间变化的细胞内区室化情况。只有这样,才有可能针对特定应用优化下一代聚合物疗法。本研究的目的是建立一种针对B16F10小鼠黑色素瘤细胞的亚细胞分级分离方法,随后用它来确定与N -(2 - 羟丙基甲基丙烯酰胺)(HPMA)共聚物结合的阿霉素(PK1)的细胞内转运情况。游离阿霉素用作对照。采用细胞破碎法实现细胞裂解,并进行优化以可重复地达到约90%的裂解效率。这确保了后续的亚细胞分级分离实验对整个细胞群体具有代表性。为了表征通过差速离心获得的亚细胞级分,选择DNA(细胞核)、琥珀酸脱氢酶(线粒体)、N - 乙酰 - β - 葡萄糖苷酶(溶酶体)、碱性磷酸酶(质膜)和乳酸脱氢酶(细胞质)作为标志物,并对它们的测定进行了仔细验证。从B16F10细胞获得的级分的相对比活性(RSA)为:细胞核(2.2)、线粒体(4.1)、溶酶体(3.7)和细胞质(2.5)。当用于研究PK1和阿霉素在无毒浓度下的细胞内分布时,PK1在溶酶体中的时间依赖性积累很明显,并且观察到了游离阿霉素预期的核定位。活细胞荧光显微镜和共聚焦共定位研究对这些结果进行了定性确证,但通过使用这种方法,我们无法准确确定细胞器定位。总之,这里开发的B16F10亚细胞分级分离方法提供了一个有用的工具,用于比较其他聚合物偶联物的细胞内转运情况。